CJC-1295 without DAC (modified GRF 1-29)

Not FDA-approved Evidence grade X — essentially no published data Updated 2026-10-20

This page describes published research and public regulatory records. It is not medical advice. SoluneFit does not sell, supply, or recommend any compound. The SoluneFit app includes a private, on-device tracker for people who want a record of what they and their clinician have already decided — the app neither suggests compounds nor doses.

Also known as: Mod GRF 1-29, modified GRF(1-29), tetrasubstituted GRF(1-29), CJC-1295 no DAC, CJC-1295 without DAC, CJC-1295 acetate.

Regulatory status

Not approved. At FDA's Pharmacy Compounding Advisory Committee on 4 Dec 2024 the committee voted 0-13 against placing each CJC-1295 form considered (free base, acetate, DAC free base, DAC acetate) on the 503A bulk-substances list, matching FDA's recommendation [2][1]. FDA lists CJC-1295 among substances previously in category 2 (significant safety risks: immunogenicity, increased heart rate, systemic vasodilatory reactions) whose nominations were withdrawn [3]. Not on the 503A bulk list, so it cannot lawfully be compounded from bulk under 503A.

What it is

GHRH analogue (29-amino-acid GRF(1-29) with four amino-acid substitutions: D-Ala2, Gln8, Ala15, Leu27; no albumin-binding linker).

The peptide core of CJC-1295 sold without the albumin-binding 'DAC' linker. The substitutions are meant to slow breakdown of native GRF(1-29) so that each injection gives a short GH pulse. It has never been studied as a medicine in its own right.

What the published research shows

FDA's 2024 review found no pharmacological studies of CJC-1295 without DAC and said data on the DAC form cannot be extrapolated to it. The only related papers are DAC-conjugate studies (rats, then healthy adults).

Published human studies and reports (these describe trial populations, not SoluneFit claims):

No human study of this compound: FDA (2024): 'The nominations did not include, and ... FDA has not identified pharmacological studies of CJC-1295 (free base) or CJC-1295 acetate.' The 2024 compounding nomination proposed a 2,000 µg/mL subcutaneous injection for GH deficiency; this was a nomination, not a studied use.

Mechanism, as reported

Binds the GHRH receptor on pituitary somatotrophs and triggers growth-hormone release, like native GHRH. Without DAC it does not attach to albumin, so it is expected to act for minutes to hours rather than days, but that has not been measured.

Practical record

Elimination half-life: 0.5 h (confidence: low). NOT MEASURED: no published PK for the non-DAC analogue, and FDA notes no study has compared its half-life with the DAC form. The app's 30 min is an inference from native GHRH kinetics: GRH(1-44) half-life 6.8 min IV in humans (Frohman 1986); native GRF(1-29) detectable only up to 1 h in rats versus 72 h for the DAC conjugate (Jetté 2005). Treat the curve as a guess.
Studied routes: subcutaneous.
Typical supply: Sold as lyophilised powder vials on the research-chemical market (no approved product).

Safety signals on record

Reported adverse events: No human safety data for this exact molecule. Related GHRH analogues commonly cause injection-site reactions, flushing and headache.
Contraindications: None established (no label).
Interactions: None documented.
Notes: WADA Prohibited List 2026 (in force 1 Jan 2026), S2.2.4: 'GHRH and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)' are prohibited at all times, in and out of competition, as non-specified substances. Vendors often label this product just 'CJC-1295', which is the name of the week-long DAC form; their expected durations differ by hundreds of times. FDA notes immunogenicity and impurity concerns for compounded CJC-1295 [3].

Sources

General wellness education, not medical advice. Unapproved compounds have no established dosing, purity standard, or safety profile.

← All compounds